Filtered By:
Source: European Heart Journal

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 332 results found since Jan 2013.

Stroke: cardiac causes and their management
Source: European Heart Journal - September 14, 2015 Category: Cardiology Authors: Luscher, T. F. Tags: ISSUE @ A GLANCE Source Type: research

Ischaemic stroke and ST-segment elevation myocardial infarction: fast-track single-stop approach
Source: European Heart Journal - September 14, 2015 Category: Cardiology Authors: Lanzer, P., Widimsky, P. Tags: CURRENT OPINION Source Type: research

Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction
Conclusion Thrombectomy was associated with a significant increase in stroke. Based on these findings, future trials must carefully collect stroke to determine safety in addition to efficacy.
Source: European Heart Journal - September 14, 2015 Category: Cardiology Authors: Jolly, S. S., Cairns, J. A., Yusuf, S., Meeks, B., Gao, P., Hart, R. G., Kedev, S., Stankovic, G., Moreno, R., Horak, D., Kassam, S., Rokoss, M. J., Leung, R. C. M., El-Omar, M., Romppanen, H. O., Alazzoni, A., Alak, A., Fung, A., Alexopoulos, D., Schwalm Tags: Interventional cardiology Source Type: research

Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials
Conclusion In centres with advanced systems of stroke care, EVT significantly improved functional outcomes (without compromising safety) in patients with acute ischaemic stroke due to anterior circulation, large artery occlusion, compared with standard therapy.
Source: European Heart Journal - September 14, 2015 Category: Cardiology Authors: Sardar, P., Chatterjee, S., Giri, J., Kundu, A., Tandar, A., Sen, P., Nairooz, R., Huston, J., Ryan, J. J., Bashir, R., Parikh, S. A., White, C. J., Meyers, P. M., Mukherjee, D., Majersik, J. J., Gray, W. A. Tags: Vascular medicine Source Type: research

Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis
Conclusion We did not find a statistically significant difference comparing OAC with APT; our results justify randomized trials comparing different antithrombotic approaches in these patients.
Source: European Heart Journal - September 14, 2015 Category: Cardiology Authors: Kent, D. M., Dahabreh, I. J., Ruthazer, R., Furlan, A. J., Weimar, C., Serena, J., Meier, B., Mattle, H. P., Di Angelantonio, E., Paciaroni, M., Schuchlenz, H., Homma, S., Lutz, J. S., Thaler, D. E. Tags: Thrombosis and antithrombotic therapy Source Type: research

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two- to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular ri...
Source: European Heart Journal - September 7, 2015 Category: Cardiology Authors: Ferrannini, E., DeFronzo, R. A. Tags: Clinical update Source Type: research

Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
Conclusions The blinded placebo-controlled STOP-HF trial demonstrated the safety of a single endocardial administration of pSDF-1 but failed to demonstrate its primary endpoint of improved composite score at 4 months after treatment. Through a pre-specified analysis the STOP-HF trial demonstrates the potential for attenuating LV remodelling and improving EF in high-risk ischaemic cardiomyopathy. The safety profile supports repeat dosing with pSDF-1 and the degree of left ventricular remodelling suggests the potential for improved outcomes in larger future trials.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Chung, E. S., Miller, L., Patel, A. N., Anderson, R. D., Mendelsohn, F. O., Traverse, J., Silver, K. H., Shin, J., Ewald, G., Farr, M. J., Anwaruddin, S., Plat, F., Fisher, S. J., AuWerter, A. T., Pastore, J. M., Aras, R., Penn, M. S. Tags: Heart failure/cardiomyopathy Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research

A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial
Conclusion TriGuard cerebral protection during TAVI is safe and complete cerebral vessel coverage was achieved in 89% of subjects. In this exploratory study, subjects undergoing protected TAVI had more freedom from ischaemic brain lesions, fewer neurologic deficits, and improved cognitive function in some domains at discharge and 30 days compared with controls.
Source: European Heart Journal - August 14, 2015 Category: Cardiology Authors: Lansky, A. J., Schofer, J., Tchetche, D., Stella, P., Pietras, C. G., Parise, H., Abrams, K., Forrest, J. K., Cleman, M., Reinohl, J., Cuisset, T., Blackman, D., Bolotin, G., Spitzer, S., Kappert, U., Gilard, M., Modine, T., Hildick-Smith, D., Haude, M., Tags: FASTTRACK EuroPCR Source Type: research

Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data
Conclusion The fusion AVAi reclassifies 52% of normal flow–low gradient and 12% of low flow–low gradient severe AS into true moderate AS, by providing true cross-sectional LVOT area.
Source: European Heart Journal - August 14, 2015 Category: Cardiology Authors: Kamperidis, V., van Rosendael, P. J., Katsanos, S., van der Kley, F., Regeer, M., Al Amri, I., Sianos, G., Marsan, N. A., Delgado, V., Bax, J. J. Tags: Valvular heart disease Source Type: research

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Conclusions LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration https://clinicaltrials.gov/, NCT01035255.
Source: European Heart Journal - August 7, 2015 Category: Cardiology Authors: Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., Solomon, S. D. Tags: Heart failure/cardiomyopathy Source Type: research

CardioPulse Articles * Editors' network of the European Society of Cardiology National Cardiovascular Journals: scientific input from the National Societies * Hand grip strength predicts myocardial infarction and stroke * Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Source: European Heart Journal - August 3, 2015 Category: Cardiology Tags: CardioPulse Source Type: research

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Conclusion In patients with ACS, ticagrelor pharmacokinetics is influenced by three genetic loci (SLCO1B1, UGT2B7, and CYP3A4). However, the modest genetic effects on ticagrelor plasma levels did not translate into any detectable effect on efficacy or safety during ticagrelor treatment. Clinical trial registration NCT00391872
Source: European Heart Journal - August 3, 2015 Category: Cardiology Authors: Varenhorst, C., Eriksson, N., Johansson, A., Barratt, B. J., Hagstrom, E., Akerblom, A., Syvanen, A.-C., Becker, R. C., James, S. K., Katus, H. A., Husted, S., Steg, P. G., Siegbahn, A., Voora, D., Teng, R., Storey, R. F., Wallentin, L., on behalf of the Tags: Acute coronary syndromes Source Type: research

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
Conclusion In patients undergoing CA for AF, the use of uninterrupted oral rivaroxaban was feasible and event rates were similar to those for uninterrupted VKA therapy. Name of the Trial Registry Clinicaltrials.gov trial registration number is NCT01729871.
Source: European Heart Journal - July 21, 2015 Category: Cardiology Authors: Cappato, R., Marchlinski, F. E., Hohnloser, S. H., Naccarelli, G. V., Xiang, J., Wilber, D. J., Ma, C.-S., Hess, S., Wells, D. S., Juang, G., Vijgen, J., Hugl, B. J., Balasubramaniam, R., De Chillou, C., Davies, D. W., Fields, L. E., Natale, A., on behalf Tags: Atrial fibrillation Source Type: research

Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project
Conclusion In patients with non-valvular AF, left-sided valvular heart disease (excluding mitral stenosis and protheses) was associated with an increased risk of stroke/TE events. A higher CHA2DS2VASc score in these patients is likely to explain these results.
Source: European Heart Journal - July 21, 2015 Category: Cardiology Authors: Philippart, R., Brunet-Bernard, A., Clementy, N., Bourguignon, T., Mirza, A., Babuty, D., Angoulvant, D., Lip, G. Y. H., Fauchier, L. Tags: CLINICAL RESEARCH Source Type: research